12:26 PM EDT, 06/06/2024 (MT Newswires) -- Novavax ( NVAX ) said Thursday that the US Food and Drug Administration has completed the filing review of the company's biologics license application for its Covid-19 vaccine and set a review target date of April 2025.

As a result, the company said commercial sales of its Covid-19 vaccine during the 2024 to 2025 season in the US will be made under its existing emergency use authorization.

Shares of the company fell 3.4% in recent trading.

Price: 20.26, Change: -0.71, Percent Change: -3.39